HALEON PLC (HLN)

London
275.55
+1.35(+0.49%)
  • Volume:
    1,429,977
  • Bid/Ask:
    275.55/275.65
  • Day's Range:
    271.20 - 275.90

HLN Overview

Prev. Close
274.2
Day's Range
271.2-275.9
Revenue
7.46B
Open
272.85
52 wk Range
241.17-337.4
EPS
1,416
Volume
1,429,977
Market Cap
25.32B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
26,331,595
P/E Ratio
0.002
Beta
-
1-Year Change
-
Shares Outstanding
9,234,573,831
Next Earnings Date
10 Nov 2022
What is your sentiment on HALEON?
or
Vote to see community's results!

HALEON PLC News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

HALEON PLC Company Profile

HALEON PLC Company Profile

Employees
22800

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyNeutralNeutral
Technical IndicatorsStrong BuyStrong BuyStrong BuyBuyBuy
SummaryStrong BuyStrong BuyStrong BuyNeutralNeutral
  • What the *****is going on with Haleon? The share price has dropped off a cliff since Wednesday.
    0
    • law suits relating to zantac
      0
    • Massive over valuation
      0
  • Significantly undervalued
    1
    • Difficult to know what to do with these. My default is to hold, but I am concerned.
      0
      • They are born out of the fantasies of that loser Walmsley. tSo they can only go down
        0
      • I actually sold mine this morning......
        0
      • Wise move, methinks. I held out hoping they might go above 3.20 and missed the boat. I won't make that mistake again, 3.20 and out!
        0
    • Overpriced for a company with only 2 good consumer health products. No wonder gsk is spinning it off
      0
      • You better sell your 50,000  and quick !
        0
    • to the moon!
      0
      • dump
        0
        • Appears cheap given that GSK rejected a 50billion bid just a few months ago. Reduced or delayed dividend will allow 10billion debt to be paid down quickly, so appears undervalued.
          3
          • Great opportunity be bold buy this for the feature..
            0
            • perhaps lets wait a while see what it settles at.
              0